Yeungnam University College Of Medicine

This phase 3 trial is testing a personalized treatment plan using high-dose aflibercept (8 mg) for people with polypoidal choroidal vasculopathy (PCV), a condition that causes vision loss. The goal is to see if adjusting the injection schedule based on each person's response can …

This Phase 3 trial is testing faricimab (Vabysmo) in 50 people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if a personalized treat-and-extend schedule can maintain vision while allowing longer gap…